Shanghai Pharmaceuticals Holding Future Growth
Future criteria checks 3/6
Shanghai Pharmaceuticals Holding is forecast to grow earnings and revenue by 17.8% and 10.2% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be 7.9% in 3 years.
Key information
17.8%
Earnings growth rate
17.8%
EPS growth rate
Healthcare earnings growth | 19.3% |
Revenue growth rate | 10.2% |
Future return on equity | 7.9% |
Analyst coverage | Good |
Last updated | 03 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 344,421 | 6,554 | 3,124 | 6,476 | 7 |
12/31/2025 | 309,724 | 5,594 | 2,863 | 6,441 | 9 |
12/31/2024 | 281,241 | 4,873 | 2,615 | 6,038 | 8 |
6/30/2024 | 267,116 | 4,100 | 1,248 | 4,108 | N/A |
3/31/2024 | 264,221 | 3,793 | -769 | 2,381 | N/A |
12/31/2023 | 260,295 | 3,768 | 2,261 | 5,232 | N/A |
9/30/2023 | 254,878 | 4,600 | 4,189 | 7,205 | N/A |
6/30/2023 | 252,866 | 4,531 | 3,774 | 6,938 | N/A |
3/31/2023 | 241,310 | 5,884 | 1,813 | 4,610 | N/A |
12/31/2022 | 231,981 | 5,617 | 2,058 | 4,743 | N/A |
9/30/2022 | 229,463 | 5,423 | -2,313 | 1,978 | N/A |
6/30/2022 | 222,294 | 5,221 | -1,659 | 2,334 | N/A |
3/31/2022 | 221,122 | 4,224 | -443 | 3,671 | N/A |
12/31/2021 | 215,824 | 5,093 | 943 | 5,061 | N/A |
9/30/2021 | 212,559 | 5,378 | 2,013 | 4,571 | N/A |
6/30/2021 | 209,982 | 5,621 | 2,863 | 5,310 | N/A |
3/31/2021 | 203,061 | 5,578 | 3,485 | 6,337 | N/A |
12/31/2020 | 191,909 | 4,496 | 3,835 | 6,845 | N/A |
9/30/2020 | 186,271 | 4,284 | 4,982 | 8,288 | N/A |
6/30/2020 | 181,156 | 4,237 | 4,118 | 7,705 | N/A |
3/31/2020 | 181,007 | 3,993 | 2,194 | 5,277 | N/A |
12/31/2019 | 186,566 | 4,081 | 3,269 | 6,022 | N/A |
9/30/2019 | 182,100 | 3,908 | 2,030 | 4,334 | N/A |
6/30/2019 | 175,781 | 4,134 | 2,167 | 4,077 | N/A |
3/31/2019 | 168,705 | 3,987 | 1,296 | 3,193 | N/A |
12/31/2018 | 159,084 | 3,881 | 1,192 | 3,135 | N/A |
9/30/2018 | 149,417 | 4,204 | 655 | 2,536 | N/A |
6/30/2018 | 140,947 | 3,629 | 520 | 2,470 | N/A |
3/31/2018 | 134,104 | 3,541 | N/A | 2,368 | N/A |
12/31/2017 | 130,847 | 3,521 | N/A | 2,649 | N/A |
9/30/2017 | 129,279 | 3,428 | N/A | 2,483 | N/A |
6/30/2017 | 126,848 | 3,389 | N/A | 2,401 | N/A |
3/31/2017 | 124,619 | 3,306 | N/A | 1,995 | N/A |
12/31/2016 | 120,765 | 3,196 | N/A | 1,947 | N/A |
9/30/2016 | 116,993 | 3,155 | N/A | 1,989 | N/A |
6/30/2016 | 114,262 | 3,075 | N/A | 1,672 | N/A |
3/31/2016 | 109,667 | 3,033 | N/A | 1,819 | N/A |
12/31/2015 | 105,517 | 2,877 | N/A | 1,349 | N/A |
9/30/2015 | 102,723 | 2,857 | N/A | 1,265 | N/A |
6/30/2015 | 99,336 | 2,807 | N/A | 1,547 | N/A |
3/31/2015 | 96,250 | 2,738 | N/A | 1,758 | N/A |
12/31/2014 | 92,399 | 2,591 | N/A | 1,336 | N/A |
9/30/2014 | 88,881 | 2,477 | N/A | 1,161 | N/A |
6/30/2014 | 83,518 | 2,371 | N/A | 906 | N/A |
3/31/2014 | 79,907 | 2,174 | N/A | 667 | N/A |
12/31/2013 | 78,223 | 2,214 | N/A | 973 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2607's forecast earnings growth (17.8% per year) is above the savings rate (2.3%).
Earnings vs Market: 2607's earnings (17.8% per year) are forecast to grow faster than the Hong Kong market (12.2% per year).
High Growth Earnings: 2607's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2607's revenue (10.2% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 2607's revenue (10.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2607's Return on Equity is forecast to be low in 3 years time (7.9%).